Product Description: Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM[1].
Applications: Cancer-programmed cell death
Formula: C21H25N5O4S
Citations: Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L104-L114./Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1070-L1080. /Ann Hematol. 2014 Sep;93(9):1499-508./Arch Biochem Biophys. 2021 Jul 31;109000./Arch Biochem Biophys. 2022 May 30;721:109194./Bioact Mater. 2024 Apr, 34, Pages 366-380./Biochem Biophys Res Commun. 2017 Jan 29;483(1):223-229. /Biochem Biophys Res Commun. 2018 Nov 17;506(1):108-113. /Biochem Biophys Res Commun. 2019 Sep 3;516(4):1242-1247. /Biochem Biophys Res Commun. 2021 Mar 3;549:150-156./Biochem Biophys Res Commun. 2019 Jan 15;508(3):986-990. /Biochem Pharmacol. 2024 May:223:116198./Bioorg Chem. 2024 Jun 24:150:107590./bioRxiv. 2023 Feb 15./bioRxiv. 2023 Feb 23./bioRxiv. 2023 Jun 5./bioRxiv. 2024 Jan 28./bioRxiv. 2024 July 08./bioRxiv. 2024 June 12./bioRxiv. 2024 November 28./bioRxiv. 2024 Sep 27:2024.09.25.615094./bioRxiv. 2024 September 19./bioRxiv. 2024 September 26./bioRxiv. April./Biosci Biotechnol Biochem. 2024 Sep 27:zbae131./Biosci Rep. 2022 Jul 26;BSR20220994./Cancer Cell. 2020 Mar 16;37(3):371-386.e12./Cancer Chemother Pharmacol. 2018 Jun;81(6):1083-1093./Cancers. 2019 Jan 15;11(1):97./Cell Biosci. 2020 Nov 27;10(1):139./Cell Chem Biol. 2021 Jul 15;S2451-9456(21)00312-3./Cell Cycle. 2019 Sep;18(18):2307-2322./Cell Death Differ. 2020 Apr;27(4):1383-1397. /Cell Death Differ. 2021 Jul 2./Cell Death Discov. 2022 Jul 12;8(1):316./Cell Death Discov. 2022 May 2;8(1):238./Cell Death Discov. 2024 Oct 26;10(1):453./Cell Metab. 2023 Jul 28;S1550-4131(23)00263-2./Cell Rep Med. 2024 Jul 16;5(7):101653./Cell Rep. 2021 Aug 24;36(8):109568./Cell Rep. 2021 Jul 20;36(3):109394./Cell Rep. 2024 Feb 27;43(2):113749./Cell Res. 2021 Mar;31(3):291-311./Cell Stem Cell. 2024 Jun 21:S1934-5909(24)00210-8./Cell. 2019 Jul 11;178(2):330-345.e22./Cell. 2023 Apr 27;186(9):1895-1911.e21./Cells. 2020 Mar 30;9(4):834./Cells. 2021, 10(11), 2803./Clin Transl Med. 2020 Jun;10(2):e113./Commun Biol. 2021 Sep 13;4(1):1066./Comput Struct Biotechnol J. 1 October 2021./Dev Cell. 2019 Feb 11;48(3):329-344.e5./Elife. 2016 Apr 11;5:e14087./Elife. 2018 Aug 1;7:e38430. /Elife. 2020 Jun 2;9:e54954./Elife. 2019 Mar 25;8:e45457. /EMBO J. 2019 Dec 2;38(23):e101409./Eur J Med Chem. 2023 Aug 19, 115732./Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280./Exp Cell Res. 2020 Jul 15;392(2):112038./FASEB J. 2021 Aug;35(8):e21800./Front Cell Dev Biol. 2021 Apr 30./Front Cell Dev Biol. 2021 Apr 30;9:667435./Front Immunol. 2022 Jul 4;13:925702./Front Oncol. 2017 Dec 11;7:293./Front Oncol. 2022 Jan 26;12:822039./Harvard University. 2023 Mar. 30487357./Institut für Pharmazeutische Wissenschaften. 2020 Nov./Institute of Molecular Virology. Ulm University. 2017 Jan./Int Immunopharmacol. 2024 Jul 21:139:112716./Int J Biol Macromol. 2024 Sep 17:135764./Int J Med Sci. 2018 Apr 3;15(7):674-681./Int J Mol Sci. 2023, 24(4), 3415./iScience. 2023 Mar./J Anim Sci. 2024 Aug 27./J Biol Chem. 15 October 2021, 101307./J Biol Chem. 2022 Sep 12;102484./J Biol Chem. 2024 Jul 1:107512./J Cell Physiol. 2022 May 16./J Cell Physiol. 2024 Oct 7:e31459./J Exp Med. 2018 Aug 6;215(8):1999-2017. /J Immunol. 2021 Jun 28;ji2001167./J Med Chem. 2021 Dec 29./J Med Chem. 2021 Jun 17./J Med Chem. 2023 Jun 30./J Med Chem. 2023 Mar 9./J Med Chem. 2023 Sep 6./J Med Chem. 2024 Jul 24./J Med Chem. 2024 Oct 10./J Med Chem. 2024 Oct 15./J Virol. 2022 May 25;96(10):e0059822./J Virol. 2024 Feb 20;98(2):e0190923./Lab Invest. 2019 Apr;99(4):528-538./Mbio. 2020 Jul 14;11(4):e00782-20./Mol Cancer Res. 2023 Feb 8;MCR-22-0648./Mol Cell. 2022 Feb 17;S1097-2765(22)00085-5./Mol Cell. 2023 Nov 16:S1097-2765(23)00913-9./Mol Metab. 2021 Jun 18;101275./Mol Ther Oncolytics. 2020 Jun 23;18:215-225./Nat Chem Biol. 2023 Aug 31./Nat Chem Biol. 2023 Sep 7./Nat Chem Biol. 2024 Jul 29./Nat Chem Biol. 2024 Mar 21./Nat Commun. 2017 May 22;8:15398. /Nat Commun. 2018 Sep 18;9(1):3801. /Nat Commun. 2021 Sep 10;12(1):5386./Nat Commun. 2022 Oct 10;13(1):5973./Nat Commun. 2022 Sep 2;13(1):5173./Nat Commun. 2024 Aug 17;15(1):7089./Nat Commun. 2024 Dec 3;15(1):10536./Nat Commun. 2024 Jan 11;15(1):468./Nat Commun. 2024 Jul 3;15(1):5604./Nat Commun. 2024 Jun 26;15(1):5409./Nat Microbiol. 2019 May;4(5):813-825./Nat Plants. 2019 Jan;5(1):34-40. /Nat Struct Mol Biol. 2024 Jan 4./Nature Cancer. 2021 Apr;2(4):429-443./Nature. 2020 Dec;588(7836):164-168./Nature. 2025 Jan 29./Neoplasia. 2022 Jul 27;32:100823./Neurobiol Dis. 2020 Sep;143:105013./Oncol Lett. 2019 Sep;18(3):2724-2732. /Oncotarget. 2016 Jun 14;7(24):35643-35654./Oncotarget. 2016 Oct 4;7(40):66087-66099./Oncotarget. 2017 Sep 23;8(49):86395-86409. /Patent. US20180263995A1./Patent. US20220175722A1./Patent. US20220280649A1./Patent. US20220281931A1./Patent. US20220378919A1./Patent. US20240190838A1./Pharmaceuticals. 2024 May 11./Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2111737119./Protein Sci. 2021 Aug 30./Redox Biol. 2021 Aug 24;46:102114./Research Square Preprint. 2021 Jun./Research Square Preprint. 2022 Jul./Research Square Print. 2022./Sci Adv. 2024 Apr 12;10(15):eadm7600./Signal Transduct Target Ther. 2024 Jan 15;9(1):18./Technol Cancer Res Treat. 2016 Aug;15(4):527-34. /University of Southern California. 2024./Virology. 2015 Mar;477:10-7. /Viruses. 2023 Nov 30, 15(12), 2356./bioRxiv. 2024 July 01./Harvard Medical School LINCS LIBRARY/J Pathol. 2021 Feb 27./Oncotarget. 2017 Oct 12;8(57):97178-97186. /Sci Adv. 2022 Sep 23;8(38):eabq4831.
References: [1]Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009 Apr 9;458(7239):732-6./[2]F S Wolenski, et al. The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. Cell Death Discovery 1, Article number: 15034 (2015)
CAS Number: 905579-51-3
Molecular Weight: 443.52
Compound Purity: 99.98
Research Area: Cancer
Solubility: DMSO : 62.5 mg/mL (ultrasonic)
Target: NEDD8-activating Enzyme
English
Deutsch
